Recoding RNA editing of antizyme inhibitor 1 predisposes to hepatocellular carcinoma
Leilei Chen,Yan Li,Chi Ho Lin,Tim Hon,Man Chan,Raymond Kwok,Kei Chow,Yangyang Song,Ming Liu,Yun-Fei Yuan,Li Fu,Kar Lok Kong,Lihua Qi,Na Zhang,Amy Hin Yan Tong,Lai-Wan Kwong,Kwan Man,Chung Mau Lo,Si Lok,Daniel G. Tenen,Xin-Yuan Guan
2012-01-01
Abstract:Better understanding of human hepatocellular carcinoma (HCC) pathogenesis at the molecular level will facilitate the discovery of tumor initiating events. Herein, transcriptome sequencing revealed that adenosine (A)-to-inosine (I) RNA editing of antizyme inhibitor 1 (AZIN1) displays a high modification rate in HCC specimens. A-to-I editing of AZIN1 transcripts is specifically regulated by adenosine deaminase acting on RNA-1 (ADAR1). The serine (S) → glycine (G) substitution at residue 367, located in β-strand 15 (β15), predicted a conformational change, induced a cytoplasmic-to-nuclear translocation, and conferred “gain-of-function” phenotypes manifested by augmented tumor initiating potential and more aggressive behavior. Compared with wild-type AZIN1 protein, the edited form possesses stronger affinity to antizyme, and the resultant higher protein stability promotes cell proliferation via the neutralization of antizyme-mediated degradation of ornithine decarboxylase (ODC) and cyclin D1 (CCND1). Collectively, A-to-I RNA Correspondence should be addressed to: Professor Xin-Yuan Guan, PhD, Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Room 56, 10/F, Laboratory Block, 21 Sassoon Road, Pok Fu Lam, Hong Kong. Tel: (852) 2819-9785; Fax: (852) 2816-9126; xyguan@hkucc.hku.hk. Daniel G. Tenen, Cancer Science Institute of Singapore, #12-01, MD6, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599; csidgt@nus.edu.sg. *These authors contributed equally to this work. AUTHOR CONTRIBUTIONS L.C., Y.L., and X.Y.G. initiated and designed the study. L.C. wrote the manuscript with input from D.G.T. and X.Y.G. L.C., Y.L., and C.L. designed the experiments and interpreted the results. L.C. and Y.L. performed all experiments with assistance from T.C., Y.S., M.L., L.Q., and R.C. Illumina mRNA library preparation was performed by N.Z. and A.T. C.L. and S.L. performed all bioinformatics analysis of transcriptome sequencing. HCC clinical sample and the relevant clinical information were provided by Y.F.Y. and extracted by L.C. and Y.L. Healthy human liver tissues were provided by K.M. and C.M.L. Human PBMCs were collected by L.F. NPC samples were provided and extracted by D.K., K. K., and L.C. D.G.T and X.Y.G. supervised the project. COMPETING FINANCIAL INTERESTS The authors declare no competing financial interests. NIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2013 September 25. Published in final edited form as: Nat Med. 2013 February ; 19(2): 209–216. doi:10.1038/nm.3043. N IH PA Athor M anscript N IH PA Athor M anscript N IH PA Athor M anscript editing of AZIN1 may be a potential driver in the pathogenesis of human cancers, particularly HCC.